Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

The next six months may be decisive for the biotech.

CryptoAlerta — análise de criptomoedas e mercado em tempo real